Douglas Krakower, MD

home / authors / douglas-krakower-md

Articles

Opportunities for HIV PrEP in Population Health

Douglas Krakower, MD;Moti Ramgopal, MD, FACP, FIDSA

March 15th 2022

The benefits of addressing barriers and increasing access to HIV PrEP therapies to high-risk populations across the globe.

Long-Acting Injectable PrEP Therapy for HIV

Douglas Krakower, MD;Ryan Bitton, PharmD, MBA

March 15th 2022

Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.

Addressing Disparities and Increasing Access to HIV PrEP

Douglas Krakower, MD;Moti Ramgopal, MD, FACP, FIDSA

March 1st 2022

Strategies that can help address disparities in care for patients with HIV and reach high-risk groups of patients to ensure access to screening and PrEP.

Population Health and HIV PrEP

Douglas Krakower, MD;Ryan Bitton, PharmD, MBA

February 15th 2022

Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.

Economic Impact of HIV

Moti Ramgopal, MD, FACP, FIDSA;Douglas Krakower, MD

February 15th 2022

The financial burden associated with HIV and the potential effects of PrEP uptake on overall costs of care.

Increasing the Uptake of HIV PrEP in the Community

Douglas Krakower, MD;Moti Ramgopal, MD, FACP, FIDSA

February 8th 2022

Considerations to help identify and increase utilization of PrEP therapy among patients who are eligible for treatment.